Member Info for Soupdragon78

Indeed Jiving, and nice to see it on an up day, rather than the usual down day.

Still a lot of traders flipping in and out, some silly sod bought and sold within ten mins earlier losing 200 quid.

Got a few questions lined up, will see if we get an update in the morning that answers any of them before submitting. I just hope folk ask decent questions that Dan can answer rather than 'is the company in talks with xyz' or 'why don't you have a dance themed tiktok channel' etc.

The twits are so rampy pampy they are trying to say Oxilio are licensing nxp001 for £20m!

These guys are shameless.

Twitter pump and dump teams active this morning

Must be having a whip round in Spoons given the lack of news today.

Well done on pocketing some cash chab.
Let’s see what the next few days brings.

I’ll have an outside bet on Dodgy Dave Tapolczay and Leaky Alan Chorlton making a leftfield offer of a multipack of Fanta and a box of Ladbrokes bookies pens for the company.

https://nuformix.com/

Looks like a few taking a position in case of something positive coming up.

Meanwhile the twits seem to think NFX have 'commenced discussions' with Oxilio to license NXP001, lol... they're only a year and a half behind reality.

Regeneriix is getting along….

Wouldn’t necessarily rule that out FX

Oxford, UK; November 6th, 2022 - Oxilio, a pioneering drug development company repurposing existing drugs to address unmet needs in cancer treatment, today announced that it has commenced first human subject dosing with OXL001. This first study is designed to investigate the pharmacokinetics (PK) and safety of various doses of OXL001 in healthy volunteers.

https://www.oxilio.co.uk/_files/ugd/c10355_88ea7bbee52f44548187c3a1aa7af806.pdf

Just a reminder of Julian Gilbert’s background. When he was in charge of Arakis, they repurposed glycopyrronium for chronic obstructive pulmonary disease (COPD), then licensed it to Novartis for $375m

https://www.biospace.com/article/around-the-web/arakis-vectura-enter-potential-375m-novartis-deal-for-ad-237/

Hope the company aren't purely doing a Q&A to satisfy a small number of traders who want to exit.

For me any PR has to be related to a news event, rather than just reiterating what is already know.

Filter, the question is around the timing.

If all they are doing is talking about things already in the public domain, then this could have happened a month ago. So why now?

So it could be related to a number of things.

They could release development news next week that forms the basis of the presentation.

They could be using the presentation as part of IR for a placing, I.e showing us small pi’s the presentation they would be should bigger fish behind closed doors.

Either way I think it’ll be related to some form of news.

Good to see this level of engagement. As FX says they really need to have something new to talk about by Wednesday or it’ll be very uncomfortable

Not so worried about timing of news, I think there will be something soon. The problems is confidence as to whether its good or bad.

Ta. very much.

Also trying to find a copy of the research note on Oxilio by ACF Equity.

Ralph Browning gives them a testimonial on their homepage, just can't find anything yet on the actual note.

https://acfequityresearch.com/

"Ralph Browning, Co-founder
Oxilio Ltd (Biotech Oncology)

We needed the investment research to be independent and credible and it needed to be written in a way that was suitable for the range of investor audiences we had in mind and this is what ACF Equity Research delivered for us. "

Anyhow, looks like Oxilio's phase 1 trial of OXL001 runs through to late Feb 2023 now. tick...tock.

https://webcache.googleusercontent.com/search?q=cache:har_rq9DM_IJ:https://www.weneedyou.co.uk/current-trials/541-six-2-night-stays/&cd=3&hl=en&ct=clnk&gl=uk

https://www.isrctn.com/ISRCTN51392723

Given they seem to think their valuation is exponential maybe the should.

They seem happy with the research note that ACF Equity Research provided for them, I guess they managed to persuade them of their valuation as a swap for Ralph Browning endorsing ACF's website. Perhaps NFX should switch to ACF instead of Stanfords.

If anyone wants to earn a quick six grand for a five night stay at Quotients clinic you can sign up to be the guinea pig for Oxl001.

Did people crowd round with pitch forks and chuck eggs at them?

I guess you were there?